leuprolide acetate for depot suspension / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 138 Diseases   97 Trials   97 Trials   2610 News 
201 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
leuprolide acetate for depot suspension / Generic mfg.
ChiCTR-TRC-14005234: A Randomized Study Comparing the Side Effects and Hormonal Status of Triptorelin and Leuprorelin Following Conservative Laparoscopic Surgery for Ovarian Endometriosis in Chinese Women

Completed
4
280
 
i.m. leuprorelin ;i.m. leuprorelin
Tianjin Central Gynecology and Obstetrics Hospital; Tianjin Central Gynecology and Obstetrics Hospital, self-financing
Ovarian Endometriosis
 
 
ChiCTR-ONC-13003673: Prospective, non-intervetional, sigle centre clinical trial of leuprorelin combination with exemestane in the treatment of premature menopause metastatic breast caner

Completed
4
60
 
leuprorelin combination with exemestane
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute; Level of the institution：, Tianjin Takeda Pharmaceutical Co., Ltd.
Breast Cancer
 
 
2004-004516-22: The impact of steroid hormones on symptom provocation in patients with premenstrual dysphoric disorder.

Ongoing
4
30
Europe
leuprorelin acetate, Divigel, Progesterone, Enanton Depot, Divigel, Enanton Depot, Divigel
Uppsala University
Premenstrual Dysphoric Disorder
 
 
ChiCTR-IPR-15005971: A prospective, multicenter and randomized parallel control study on the treatment of uterine volume inducing by different Leuprorelin Acetate microspheres doses (Enantone○R) in adenomyosis.

Recruiting
4
640
 
Enantone 3.75mg ;Enantone 1.88mg ;Mirena ;oral contraceptive ;San Jie Zhen Tong capsule ;Enantone 3.75mg ;Enantone 1.88mg
Obstetrics and Gynecology Hospital of Fudan University; Obstetrics and Gynecology Hospital of Fudan University, Tianjin takeda pharmaceuticals Co. LTD
Adenomyosis
 
 
NCT02393482: Psychological Impact of Amenorrhea in Women With Endometriosis

Not yet recruiting
4
50
Europe
Estroprogestinic therapy (Etinil-estradiol/levonorgestre), Gonadotropin-releasing hormone agonist (Leuprorelin acetate), Add back therapy 1 (tibolone), Add back therapy 2 (calcium carbonate/colecalciferol)
University of Cagliari
Amenorrhea, Endometriosis, Quality of Life
12/21
06/22
NCT03963752: Clinical Trial of Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western Medicine

Completed
4
126
RoW
Ziyinxiehuo Granules Herbs, nourishing"Yin"-removing"Fire" Granules, Megestrol Acetate Tablet, Leuprorelin Acetate 3.75mg Injection
Children's Hospital of Fudan University
Idiopathic Precocious Puberty
08/22
09/22
NCT04248621: Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients

Recruiting
4
164
RoW
Leuprorelin, Leuprorelin acetate, Goserelin, Goserelin acetate, Triptorelin, Triptorelin acetate, Degarelix, Degarelix acetate, Bicalutamide, Casodex, Flutamide, Niftolide, Maximum androgen blockade, LHRN agonist and antiandrogen
Wonju Severance Christian Hospital, Eulji University Hospital
Prostatic Neoplasms
04/22
12/22
NCT03421639: Aromatase Plus GnRH Analogue Versus GnRH Analog Alone in Adenomyosis

Active, not recruiting
4
300
Europe, RoW
GnRH analog (11.25mg Leuprolide acetate), Control group, Aromatase inhibitor and GnRH analog, experimental group, Aromatase and GnRH analog (11.25mg Leuprolide acetate)
Centre for Endocrinology and Reproductive Medicine, Italy
Uterine Adenomyosis, Recurrent Implantation Failure, Menstrual Pain
09/24
09/24
2021-005005-28: Assisted reproductive technology (ART) and pregnancy outcomes in women with adenomyosis (internal endometriosis) according to stimulation protocol in relation to immunological and endometrial features: a prospective, randomized study. Esito della riproduzione assistita (ART) e della successiva gravidanza nelle donne con adenomiosi (endometriosi interna) secondo il diverso protocollo di stimolazione ovarica in relazione alle caratteristiche immunologiche ed endometriali: uno studio prospettico, randomizzato.

Not yet recruiting
4
500
Europe
Enantone, Cetrotide, Orgalutran, Visanne, Pregnyl, [-], Solution for injection, Powder and solvent for solution for injection/infusion, Tablet, Powder and solvent for solution for injection
AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA, Ministero della Salute
Women with transvaginal ultrasound (TV-US)-based diagnosis of adenomyosis and women without adenomyosis but with similar baseline reproductive risks Donne con diagnosi di adenomiosi basata sull'ecografia transvaginale (TV-US) e donne senza adenomiosi ma con rischi riproduttivi di base simili, Women with and without a diagnosis of adenomyosis with reproductive risks Donne con e senza diagnosi di adenomiosi con rischi riproduttivi, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
 
 
NCT05341115 / 2022-002471-11 / CTR20231227: A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty

Completed
4
79
RoW
Leuprorelin Acetate Depot 3M, Leuprolide acetate Depot 3M
Takeda, Takeda
Central Precocious Puberty
12/24
03/25
ADENOFERT, 2024-516089-12-00`2021-005005-28: Assisted reproductive technology (ART) and pregnancy outcomes in women with adenomyosis (internal endometriosis) according to stimulation protocol in relation to immunological and endometrial features: a prospective, randomized study

Recruiting
4
500
Europe
LEUPRORELIN , -
Azienda Ospedaliero Universitaria Di Modena, Ministero della Salute
women with transvaginal ultrasound (TV-US)-based diagnosis of adenomyosis, women without adenomyosis but with similar baseline reproductive risks
 
 
ADENOFERT, NCT05937490: Adenomyosis and ART

Recruiting
4
500
Europe
Enantone, Dienogest 2 MG (milligram), long GnRH agonist or flexible GnRH antagonist protocol.
Azienda Ospedaliero-Universitaria di Modena, University of Modena and Reggio Emilia, Ministero della Salute, Italy
Adenomyosis
03/25
03/25
NCT07710430: A Study of Leuprorelin 1-Month (4-Week) Formulation in Children With Central Precocious Puberty

Recruiting
4
43
RoW
Leuprorelin
LG Chem
Central Precocious Puberty
08/29
04/30
ARCH, NCT05700903: Contributions to Hypertension With Androgen Deprivation Therapy

Completed
4
10
US
Gonadotropin Releasing Hormone Agonists (GNRH), Leuprolide, Goserelin, Androgen receptor (AR) inhibitor, Bicalutamide, Flutamide, Enzalutamide, Placebo
University of Colorado, Denver
Androgen Deprivation Therapy, Prostate Cancer, Hypertension, Autonomic Dysfunction, Renal Disease
07/25
07/25
ChiCTR2300068147: a prospective cohort study evaluating safety and efficacy of leuprolide acetate different depot formulations in young patients with hormone receptor-positive breast cancer

Not yet recruiting
4
116
 
N/A ;N/A
Jinjiang Municipal Hospital; Jinjiang Municipal Hospital, Jinjiang Municipal Hospital
breast cancer
 
 
CTR20171179: Clinical study of uristatin acetate tablets as a preoperative treatment for symptomatic uterine fibroids.

Suspended
3
236
China
1. Generic Chinese name: Uliprelin Acetate Tablets; 2. Generic Chinese name: Uliprelin Acetate Tablets; 1. Generic Chinese name: Leuprorelin Acetate Microspheres for Injection; English name: Leuprorelin Acetate Microspheres for Injection; Trade name: YNT (a brand name).
Jireh Pharmaceutical Factory / Jireh Pharmaceutical (China) Co., Ltd.
Indications: For preoperative treatment of moderate to severe symptomatic uterine fibroids in adult women of reproductive age.
 
 
Uterine Leiomyoma-7: Phase III study of leuprorelin depot

Ongoing
3
0
RoW
Luphere (3 month depot) (leuprorelin depot)
Daewoong
Uterine Leiomyoma
 
 
Endometriosis & Endometrial Pain-10: Luphere Depot approved for endometriosis

Ongoing
3
0
RoW
Luphere (3 month depot) (leuprorelin depot)
Daewoong
Endometriosis & Endometrial Pain
 
 
2004-001720-21: A Phase III, multi-center, randomized, double-blind comparator study to evaluate the efficacy and safety of 50 mg and 100 mg of TAK-013 tablets administered twice daily versus 3.75mg of Leuprolide administered monthly for 24 weeks in subjects with symptomatic endometriosis.

Ongoing
3
200
Europe
Sufugolix, Leuprorelin acetate, TAK-013, Coated tablet, Powder for suspension for injection, Leuprorelin acetate
Takeda Europe R&D Centre Ltd
Endometriosis
 
 
ChiCTR-IIR-15007521: The efficacy and safety of using mifepristone in the treatment of uterine fibroids: a randomized, multiple-center controlled trial

Completed
3
300
 
Three months of daily therapy with oral mifepristone (at a dose of 10 mg) ;Three months of daily therapy with oral mifepristone (at a dose of 25 mg) ;once-monthly subcutaneous injections of enantone (at a dose of 3.75 mg)
Peking University First Hospital; Peking University First Hospital, CR Zizhu Pharmaceutical Co., Ltd
Uterine fibroids
 
 
RTOG 0534, NCT00567580: Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

Active, not recruiting
3
1792
Canada, US, RoW
PBRT, Prostate bed radiotherapy, Three-Dimensional Conformal Radiation Therapy (3D-CRT), Intensity modulated RT (IMRT), PLNRT, Pelvic lymph node radiotherapy, AA, flutamide, bicalutamide, LHRH agonist, leuprolide, goserelin, buserelin, triptorelin
Radiation Therapy Oncology Group, National Cancer Institute (NCI), Cancer and Leukemia Group B, NRG Oncology
Prostate Cancer
07/18
 
CALGB 90203, NCT00430183: Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

Active, not recruiting
3
788
Canada, US
docetaxel, LHRH agonist, leuprolide acetate OR, goserelin acetate, surgery
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Eastern Cooperative Oncology Group, NCIC Clinical Trials Group, Southwest Oncology Group
Prostate Cancer
10/18
10/30
CTR20171172: A phase 3 study comparing abemaciclib with or without standard endocrine therapy in early-stage breast cancer.

Completed
3
256
China
1. Generic Chinese name: Abemaciclib; 2. Generic Chinese name: Letrozole Tablets; English name: Anastrozole Tablets; Trade name: Ruiningde; 3. Generic Chinese name: Tamoxifen Citrate Tablets; English name: Tamoxifen Citrate Tablets; 4. Generic Chinese name: Toremifene Citrate Tablets; English name: Toremifene Citrate Tablets; Trade name: Faletong; 5. Generic Chinese name: Exemestane Tablets; English name: Exemestane Tablets; Trade name: Anuoxin; 6. Generic Chinese name: Goserslin Acetate Sustained-Release Depot; English name: Goserslin Acetate Sustained-Release Depot; Trade name: Nuolaide; 7. Generic Chinese name: Leuprorelin Acetate Microspheres for Injection English Name: Leuprorelin Acetate For Injiction Product Name: ???
Eli Lilly and Company / Shanghai Representative Office of Eli Lilly Asia Company
Indications: Early-stage breast cancer
 
 
RTOG 0815, NCT00936390 / 2010-020825-42: Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Completed
3
1538
Canada, US
bicalutamide, flutamide, anti-androgen therapy, LHRH agonist (antagonist) therapy, leuprolide, goserelin, buserelin, triptorelin, degarelix, Dose-Escalated Radiation Therapy
Radiation Therapy Oncology Group, National Cancer Institute (NCI), NRG Oncology
Prostate Cancer
10/20
09/25
NCT03695237 / 2022-004131-61: A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)

Completed
3
45
US
Leuprolide Acetate (LA), Lupron Depot
AbbVie, AbbVie Inc.
Central Precocious Puberty (CPP)
05/21
11/23
NCT01546987: Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Completed
3
239
Canada, US
GnRH agonist, LHRH analog, leuprolide, goserelin, buserelin, triptorelin, Gonadotropin-releasing hormone (GnRH) Agonist, LHRH agonist, Anti-androgen, flutamide, bicalutamide, androgen suppression, TAK-700, Radiation therapy
Radiation Therapy Oncology Group, National Cancer Institute (NCI), NRG Oncology
Prostate Cancer
11/21
09/25
BSV_LEUPR_18_05, NCT04914195: Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer

Completed
3
155
RoW
Leuprolide Acetate 3.75 MG/ML
Bharat Serums and Vaccines Limited
Advanced Prostate Adenocarcinoma
09/22
09/22
CTR20181413: Efficacy and safety studies of oral Relugolix in the treatment of advanced prostate cancer

Completed
3
138
China
1. Chinese Generic Name: Relugolix Tablets; 2. Chinese Generic Name: Relugolix Tablets; 1. Chinese Generic Name: Generic Name: Leuprorelin Acetate Microspheres for Injection; English Name: Leuprorelin Acetate Microspheres for Injection
Takeda Pharmaceutical Company Limited / Bushu Pharmaceuticals Ltd. Kawagoe Plant / Takeda Pharmaceutical (China) Co., Ltd.
Indications: Advanced prostate cancer
 
 
S1207, NCT01674140: Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

Active, not recruiting
3
1939
US
anastrozole, Arimidex, everolimus, Afinitor, exemestane, Aromasin, goserelin acetate, Zoladex, letrozole, Femara, leuprolide acetate, Lupron, tamoxifen citrate, nolvadex, placebo
SWOG Cancer Research Network, National Cancer Institute (NCI)
Breast Cancer
12/22
01/30
DELFINO, NCT03664895: Density Lowering Effect of "OFS Add on to TMX"( Trial)

Recruiting
3
224
RoW
Leuplin or zoladex
Seoul National University Hospital
Breast Cancer Invasive
12/24
12/24
ENDOSafe, NCT06145438: Comparing the Safety and Efficacy in the Use of Hormonal Therapy on Endometriosis Patients After Conservative Surgery

Completed
3
80
RoW
Dienogest, Nelandoz, Depo Medroxyprogesterone acetate, Depo Provera, Leuprolide (as Leuprolide Acetate), Tapros, Levonogestrel + etinilestradiol (30 mcg, brand name Mycrogynon), Combined oral contraceptive
Universitas Diponegoro
Endometriosis Ovary
08/24
11/24
NCT05169112: Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy

Recruiting
3
72
Canada
Lupron Depot
Ottawa Hospital Research Institute, Tolmar Pharmaceuticals
Prostate Cancer
11/26
11/28
CTR20220814: A study of leuprorelin injection emulsion for the treatment of advanced prostate cancer

Completed
3
133
China
1. Chinese Generic Name: Leuprolide Injectable Emulsion; English Generic Name: Leuprolide Injectable Emulsion; Trade Name: NA;
Yida Biotechnology Co., Ltd. / Changchun Jinsai Pharmaceutical Co., Ltd. / Fareva PAU 1
Indications: Advanced prostate cancer
 
 
URONCOR 06-24, NCT05781217 / 2021-006975-41: Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624

Recruiting
3
534
Europe
triptorelin, goserelin, leuprorelin
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic, GICOR
Prostate Cancer, Salvage Radiotherapy, Biochemical Recurrence, Androgen Deprivation Therapy, Metastases-free Survival
12/23
12/32
ASPAIT, NCT02914158: Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women

Recruiting
3
680
RoW
Goserelin, Tamoxifen, Aromatase Inhibitors, Leuprolide, leuprolide acetate
First Affiliated Hospital, Sun Yat-Sen University
Breast Cancer
12/23
12/25
CASPAR, NCT04455750: A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy

Active, not recruiting
3
61
US
Enzalutamide, Rucaparib camsylate, Placebo, Leuprolide Acetate, Goserelin Acetate, Degarelix, Quality-of-Life Assessment, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
03/27
09/27
NCT06490328: Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer

Recruiting
3
154
RoW
DKF-MA102, Leuprorelin acetate
Dongkook Pharmaceutical Co., Ltd.
Advanced Prostate Cancer
05/25
05/25
PRESTO, NCT03009981: A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

Completed
3
504
US
Apalutamide, Erleada, LHRH Analogue, Degarelix (Firmagon), Leuprolide (Lupron) and Bicalutamide, Abiraterone Acetate, Zytiga, Prednisone, Deltasone
Alliance Foundation Trials, LLC., Janssen Research & Development, LLC
Prostate Cancer
06/25
06/25
GenSci093-301, NCT06449027: Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.

Active, not recruiting
3
211
RoW
T Leuprolide Injectable Emulsion, Tamoxifen Citrate Tablets, Leuprorelin Acetate Microspheres for Injection
Changchun GeneScience Pharmaceutical Co., Ltd.
Breast Cancer Subjects
11/25
03/26
DETECT V, NCT02344472 / 2014-002249-22: Detect V / CHEVENDO (Chemo vs. Endo)

Active, not recruiting
3
271
Europe
pertuzumab, Perjeta®, Trastuzumab, Herceptin®, Capecitabine, Paclitaxel, Vinorelbine, Docetaxel, Exemestane, Letrozole, Anastrozole, Fulvestrant, Ribociclib, Kisqali®, nab-Paclitaxel, eribulin, leuprorelin, goserelin
Prof. Wolfgang Janni, Roche Pharma AG, Novartis Pharmaceuticals, Eisai GmbH, Celgene Corporation
Metastatic Breast Cancer
01/25
01/25
SERENA-6, NCT04964934 / 2023-503990-39-00 / 2021-000546-17: Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression

Hourglass Jul 2026 - Jul 2026 : Anticipated approval in US
Active, not recruiting
3
315
Europe, Canada, Japan, US, RoW
AZD9833, AZD9833 Placebo, Anastrozole, Anastrozole placebo, Letrozole, Letrozole placebo, Palbociclib, Abemaciclib, Luteinizing hormone-releasing hormone (LHRH) agonist, Ribociclib
AstraZeneca
ER-Positive HER2-Negative Breast Cancer
06/25
09/28
REVELUTION-2, NCT06650579: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

Recruiting
3
72
US
Abiraterone Acetate, BR9004, BR9004-1, CB 7630, CB-7630, CB7630, JNJ-212082, Yonsa, Zytiga, Bicalutamide, Casodex, Cassotide, Cosudex, ICI 176,334, ICI 176334, Utamide, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography Angiography, CT ANGIOGRAPHY, CT Scan Angiography, CTA, Leuprolide, Leuprorelin, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Relugolix, N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea, Orgovyx, Relumina, TAK 385, TAK-385, TAK385
Emory University, Pfizer, Sumitomo Pharma America, Inc., National Comprehensive Cancer Network, National Cancer Institute (NCI)
Recurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
07/29
07/29
NCT06025409: Evaluate the Efficacy and Safety of DWJ108J

Recruiting
3
79
RoW
Leuprolide Acetate 11.25 MG/ML
Daewoong Pharmaceutical Co. LTD.
Central Precocious Puberty
02/25
08/25
NCT05440383: A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia

Completed
3
287
Japan
KLH-2109, Leuprorelin
Kissei Pharmaceutical Co., Ltd.
Uterine Fibroids (MeSH Heading: Leiomyoma)
08/24
08/24
NCT07015268: A Clinical Study of KLH-2109 in Patients With Endometriosis

Active, not recruiting
3
288
Japan
KLH-2109, Leuprorelin acetate
Kissei Pharmaceutical Co., Ltd.
Endometriosis
11/27
11/27
PSMAddition, NCT04720157 / 2023-507970-42-00 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Hourglass May 2026 - May 2026 : Anticipated approval in US
Hourglass Oct 2025 - Dec 2025 : Regulatory submission in US for PSMA+ mHSPC
Hourglass Oct 2025 - Dec 2025 : Approval for PSMA positive mCRPC
Hourglass Jul 2025 - Dec 2025 : Regulatory submission in US for PSMA+ mHSPC
Jan 2024 - Dec 2024: Primary data from PSMAddition trial for metastatic hormone sensitive prostate cancer
Active, not recruiting
3
1140
Europe, Canada, Japan, US, RoW
177Lu-PSMA-617, AAA617, 68Ga-PSMA-11, ARDT, ADT
Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc.
Prostatic Neoplasms
01/25
02/27
NCT01492972: Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

Recruiting
3
192
US
Radiation, Androgen Suppression Therapy, leuprolide, goserelin, buserelin, or triptorelin
Proton Collaborative Group
Prostate Cancer
12/27
 
NoLEEta, NCT07237256 / 2025-520979-13-00: Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib

Recruiting
3
3902
Europe
Chemotherapy followed by endocrine therapy and ribociclib treatment, Ribociclib, Adjuvant hormonotherapy, De-escalation
UNICANCER, Novartis, SOLTI Breast Cancer Research Group, GBG Forschungs GmbH, Latin American Cooperative Oncology Group, Gruppo Italiano Mammella (GIM), BOOG Study Center, Canadian Cancer Trials Group, Swiss Cancer Institute, Menarini Silicon Biosystems, INC
Breast Cancer
11/33
12/37
CO44657, NCT06065748 / 2022-502980-39-00 / CTR20233896: A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Recruiting
3
1050
Europe, Canada, US, RoW
Giredestrant, RO7197597, RG6171, GDC-9545, Fulvestrant, Abemaciclib, Palbociclib, Ribociclib, LHRH Agonist, FoundationOne Liquid CDx Assay (F1LCDx), F1LCDx
Hoffmann-La Roche, F. Hoffmann La Roche
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
02/27
02/29
ENHANCE, NCT07751133: Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer

Not yet recruiting
3
1500
NA
Abiraterone, Apalutamide, Enzalutamide or Darolutamide (ARPI therapy) (per standard of care) therapy, Goserelin, Leuprolide, and Triptorelin, Degarelix or Relugolix (ADT therapy per standard of care)
University College, London, Cancer Research UK, Prostate Cancer UK, University of Manchester
Prostate Cancer, mHSPC, mCRPC
08/29
08/33
SERENA-4, NCT04711252 / 2023-503995-26-00 / 2020-002276-12 / CTR20212607: A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

Active, not recruiting
3
1370
Europe, Canada, Japan, US, RoW
camizestrant, Arimidex? 1 mg Filmtabletten, IBRANCE 75 mg hard capsules, Placebo to match camizestrant, Placebo to match Arimidex, LEUPRORELIN ACETATE, IBRANCE 125 mg hard capsules, IBRANCE 75 mg film-coated tablets, IBRANCE 100 mg hard capsules, IBRANCE 125 mg film-coated tablets, IBRANCE 100 mg film-coated tablets, GOSERELIN ACETATE, Camizestrant
AstraZeneca, AstraZeneca AB, Sweden
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
08/26
02/29
REPLACE-CV, NCT05605964: Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate

Completed
3
387
US
Relugolix, ORGOVYX, TAK-385, MVT-601, RVT-601, T-1331285, Leuprolide Acetate, Leuprolide
Sumitomo Pharma America, Inc.
Prostate Cancer
12/24
12/24
ADJUVANT WIDER, NCT05827081 / 2022-503001-38-01: Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Recruiting
3
1400
Europe, Canada, US, RoW
Ribociclib, LEE011, Letrozole, Ansastrozole, Goserelin, Leuprolide, Exemestane
Novartis Pharmaceuticals, Novartis Pharma AG
HR-positive HER-2- negative Breast Cancer
09/29
09/30
CARLHA-2, NCT04181203 / 2024-514829-36-00 / 2017-000155-21: Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy

Active, not recruiting
3
490
Europe
Apalutamide, ARN-509, Salvage radiotherapy (SRT), Luteinising Hormone Releasing Hormone agonist (LHRHa), leuprolide, goserelin, triptorelin acetate
UNICANCER, Janssen Pharmaceutica
Prostate Cancer
09/28
12/33
EORTC 2238, NCT05974774 / 2023-506817-23-01: Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors

Recruiting
3
1600
Europe
iMAB, intermittent maximum androgen blockade, cMAB, continuous maximum androgen blockade
European Organisation for Research and Treatment of Cancer - EORTC, Cancer Trials Ireland, UNICANCER, Spanish Oncology Genito-Urinary Group
Metastatic hormone na?ve prostate cancer (mHNPC)
05/35
06/39
CAMBRIA-2, NCT05952557 / 2023-504031-41-00 / CTR20233662: An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer

Recruiting
3
5500
Europe, Canada, Japan, US, RoW
Camizestrant, AZD9833, Tamoxifen, Anastrozole, Letrozole, Exemestane, Abemaciclib
AstraZeneca, Austrian Breast & Colorectal Cancer Study Group
Breast Cancer, Early Breast Cancer
03/30
05/37
ALADDIN, NCT05116475 / 2024-517285-41-00 / 2021-003542-21: Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases

Recruiting
3
152
Europe
LEUPRORELIN , Placebo to BAY 1841788 300 mg film-coated tablet, BAY 1841788, DEGARELIX , TRIPTORELIN
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie, Bayer
Newly diagnosed prostate cancer with pelvic lymph nodes metastases
02/26
02/27
GUIDANCE, NCT05050084: Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

Active, not recruiting
3
2050
Canada, US
Bicalutamide, Casodex, Cassotide, Cosudex, ICI 176,334, ICI 176334, Utamide, Buserelin, 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig), BSRL, Busereline, Etilamide, HOE 766, HOE-766, HOE766, ICI 123215, ICI-123215, ICI123215, S74 6766, S74-6766, S746766, Tiloryth, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, ODM201, Degarelix, ASP 3550, ASP-3550, ASP3550, FE 200486, FE-200486, FE200486, Firmagon, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, Sch 13521, Tafenil, Tecnoflut, Testotard, Goserelin, ICI-118630, Histrelin, Leuprolide, Leuprorelin, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Relugolix, N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea, Orgovyx, Relumina, TAK 385, TAK-385, TAK385, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY 25650, AY-25650, AY25650, CL 118532, CL-118,532, CL-118532, CL118532, Detryptoreline
NRG Oncology, National Cancer Institute (NCI)
Prostate Adenocarcinoma
11/26
11/26
PREDICT-RT, NCT04513717: Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The Trial

Active, not recruiting
3
2753
Canada, US
Apalutamide, ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927, Bicalutamide, Casodex, Cassotide, Cosudex, ICI 176,334, ICI 176334, Utamide, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Buserelin, 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig), BSRL, Busereline, Etilamide, HOE 766, HOE-766, HOE766, ICI 123215, ICI-123215, ICI123215, S74 6766, S74-6766, S746766, Tiloryth, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Degarelix, ASP 3550, ASP-3550, ASP3550, FE 200486, FE-200486, FE200486, Firmagon, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, Sch 13521, Tafenil, Tecnoflut, Testotard, Goserelin, ICI-118630, Histrelin, Leuprolide, Leuprorelin, Magnetic Resonance Elastography, MRE, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Relugolix, N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea, Orgovyx, Relumina, TAK 385, TAK-385, TAK385, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY 25650, AY-25650, AY25650, CL 118532, CL-118,532, CL-118532, CL118532, Detryptoreline
NRG Oncology, National Cancer Institute (NCI)
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
12/33
12/33
OPTIMA-YOUNG, NCT07106632 / 2024-519655-28-00: Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests

Recruiting
3
3380
Europe
test-directed treatment: allocated treatment will depend on the PAM50 score result (centrally assessed) : chemo-endocrine therapy or endocrine therapy alone, In the control arm, the treatment will be as standard of care : chemo-endocrine therapy
UNICANCER, University of Warwick
Early Breast Cancer, Premenopausal Breast Cancer, HR+/HER2- Breast Cancer
08/31
08/38
VA STARPORT, NCT04787744: Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

Recruiting
2/3
464
US
PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease, Goserelin, Histrelin, Leuprolide & Triptorelin, ADT + Nilutamide, Flutamide, & Bicalutamide, Degarelix & Relugolix, ADT + Docetaxel +/- prednisone, ADT + Abiraterone + Prednisone, ADT + Abiraterone + Methylprednisolone, ADT + Apalutamide, ADT + Enzalutamide, Prostate-directed Radiation for De novo oligometastatic prostate cancer
VA Office of Research and Development
Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer, Metastatic Prostate Cancer, De Novo Prostate Cancer
09/26
03/29
202000894, 2023-506637-30-00: The AGAINST-PLD Study; An investigator-driven, randomized, open label clinical trial assessing efficacy of leuprorelin to halt disease progression in PLD

Completed
2/3
36
Europe
LEUPRORELIN
Universitair Medisch Centrum Groningen, AbbVie
polycystic liver disease
 
 
CAAA617C12301, 2023-507970-42-00: An Open-label study comparing 177Lu-PSMA-617 plus Standard of Care vs. Standard of Care in the Treatment of mHSPC

Active, not recruiting
2/3
445
Europe
APALUTAMIDE , Pluvicto 1 000 MBq/mL solution for injection/infusion, RELUGOLIX , ABIRATERONE , -, TRIPTORELIN , LEUPRORELIN , BICALUTAMIDE , DAROLUTAMIDE , NILUTAMIDE , GOSERELIN , HISTRELIN , DEGARELIX , ENZALUTAMIDE , BUSERELIN , FLUTAMIDE , Locametz 25 micrograms kit for radiopharmaceutical preparation
Novartis Pharma AG
PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC)
 
 
1414-ROG-GUCG, 2024-513450-30-00`2015-005098-19: A research study to compare the standard treatment and the study drug (degarelix) in combination with radiotherapy in patients with high-risk localized or locally-advanced cancer, who receive this treatment after initial radical prostatectomy or as primary therapy.

Active, not recruiting
2/3
476
Europe
DEGARELIX, GOSERELIN, TRIPTORELIN, LEUPRORELIN ACETATE, TRIPTORELIN
Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi, Ferring Pharmaceuticals A/S, European Organisation for Research and Treatment of Cancer (EORTC)
very high risk localized or locally advanced prostate cancer
 
 
AFT-38, 2024-513540-29-00: Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Not yet recruiting
2/3
303
Europe
IBRANCE 125 mg hard capsules, LETROZOLE, TRIPTORELIN, ANASTROZOLE, IBRANCE 75 mg hard capsules, TRASTUZUMAB, PERTUZUMAB, GOSERELIN, IBRANCE 100 mg hard capsules, LEUPRORELIN, FULVESTRANT, EXEMESTANE
Alliance Foundation Trials LLC, Pfizer, INC.
Breast Cancer
 
 
C3431004/MDV3100-13, 2024-513521-23-00: An international study to evaluate the safety and effectiveness of enzalutamide plus leuprolide, enzalutamide alone, and leuprolide alone in men with high-risk nonmetastatic prostate cancer progressing after definitive therapy.

Active, not recruiting
2/3
366
Europe
LEUPRORELIN ACETATE, Xtandi - 40 mg soft capsules, Placebo for Enzalutamide 40 mg soft gelatin capsule
Medivation Inc., Medivation, Inc., a wholly owned subsidiary of Pfizer Inc.
Prostate Cancer
 
 
D8534C00001, 2023-503990-39-00: A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 mutation

Active, not recruiting
2/3
128
Europe
camizestrant, Placebo to match camizestrant, ABEMACICLIB, LETROZOLE, Arimidex? 1 mg Filmtabletten, GOSERELIN ACETATE, LEUPRORELIN ACETATE, IBRANCE 100 mg film-coated tablets, IBRANCE 125 mg film-coated tablets, Camizestrant, RIBOCICLIB, Placebo to match anastrozole, IBRANCE 75 mg film-coated tablets, Placebo to match letrozole
AstraZeneca AB
Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer
 
 
MEDOPP545, 2024-512926-27-00: A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors - The ADELA study-

Recruiting
2/3
214
Europe
Everolimus-ratiopharm? 2,5 mg Tabletten, GOSERELIN , ORSERDU 86 mg film-coated tablets, ORSERDU 345 mg film-coated tablets, LEUPRORELIN , DEXAMETHASONE , The investigational product is as follows: white tablets, elongated, flat, rounded edges, about 10 mm long and 4 mm wide, with the embossing "EV" on one side and "2.5" on the other side. The list of excipients of Placebo tablet is as follows: Lactose monohydrate, Polyplasdone, Cellulose microcrystalline, Magnesium stearate, Hypromellose., TRIPTORELIN
Medica Scientia Innovation Research S.L., Medica Scientia Innovation Research S.L., Stemline Therapeutics Inc., Berlin-Chemie AG
patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors.
 
 
2024-517285-41-00`2021-003542-21: ALADDIN: evaluation of dAroLutamide Addition to anDrogen Deprivation therapy and radIatioN therapy in newly diagnosed prostate cancer with pelvic lymph nodes metastases

Not yet recruiting
2/3
152
Europe
Placebo to BAY 1841788 300 mg film-coated tablet, LEUPRORELIN , BAY 1841788, DEGARELIX , TRIPTORELIN
ARTIC, Bayer
Newly diagnosed prostate cancer with pelvic lymph nodes metastases
 
 
CO44657, 2022-502980-39-00: A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Recruiting
2/3
296
Europe
Verzenios 150 mg film-coated tablets, RO7197597, IBRANCE 100 mg film-coated tablets, IBRANCE 125 mg film-coated tablets, Kisqali 200 mg film-coated tablets, Faslodex 250 mg solution for injection., LEUPRORELIN , RIBOCICLIB, Verzenios 50 mg film-coated tablets, IBRANCE 75 mg film-coated tablets, Verzenios 100 mg film-coated tablets
F. Hoffmann-La Roche AG, F. Hoffmann La Roche
Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
 
 
BOOG 2017-03, 2024-516204-42-00: Endocrine therapy plus CDK 4/6 inhibition in first- or second-line for hormone receptor positive advanced breast cancer - the SONIA study

Active, not recruiting
2/3
1050
Europe
Verzenios 100 mg film-coated tablets, IBRANCE 75 mg film-coated tablets, Kisqali 200 mg film-coated tablets, Verzenios 50 mg film-coated tablets, GOSERELIN , ESTRADIOL , Verzenios 150 mg film-coated tablets, ANASTROZOLE , FULVESTRANT , IBRANCE 100 mg film-coated tablets, LEUPRORELIN , IBRANCE 125 mg film-coated tablets, LETROZOLE
BOOG Study Center B.V.
Breast cancer
 
 
2023-507847-13-00: The RED FLASH study

Recruiting
2/3
67
Europe
TAMOXIFEN, LETROZOLE, ANASTROZOLE, FULVESTRANT, LEUPRORELIN, OXYBUTYNIN, GOSERELIN, VENLAFAXINE, EXEMESTANE
Reinier de Graaf Groep
Breast cancer
 
 
D8532C00001, 2023-503995-26-00: A Randomised, Double-Blind, Phase III Study of AZD9833 plus Palbociclib versus Anastrozole plus Palbociclib in Patients with ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease.

Active, not recruiting
2/3
499
Europe
IBRANCE 125 mg film-coated tablets, Placebo to match camizestrant, IBRANCE 75 mg film-coated tablets, IBRANCE 125 mg hard capsules, camizestrant, IBRANCE 100 mg hard capsules, IBRANCE 75 mg hard capsules, Arimidex? 1 mg Filmtabletten, IBRANCE 100 mg film-coated tablets, Placebo to match Arimidex, LEUPRORELIN ACETATE, GOSERELIN ACETATE, Camizestrant
AstraZeneca AB, AstraZeneca AB, Sweden
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
 
 
CLEE011O12001, 2022-503001-38-01: A trial to learn more about the effects of ribociclib taken with endocrine therapy in patients with early breast cancer.

Active, not recruiting
2/3
172
Europe
LEUPRORELIN ACETATE, ANASTROZOLE, GOSERELIN, LETROZOLE, EXEMESTANE, RIBOCICLIB
Novartis Pharma AG, Novartis Pharma AG
HR-positive HER-2- negative Breast Cancer
 
 
UC-GTG-2306, 2023-507482-26-00: Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imaging

Recruiting
2/3
287
Europe
LEUPRORELIN ACETATE, BAY 1841788, NUBEQA 300 mg film-coated tablets, TRIPTORELIN, DEGARELIX, GOSERELIN
Unicancer
Castrate-resistant prostate cancer with oligometastases on functional imaging (PSMA or choline/fluciclovine-positron-emission tomography).
 
 
D8535C00001, 2023-504031-41-00: An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Recruiting
2/3
2049
Europe
EXEMESTANE, TRIPTORELIN, LETROZOLE, Arimidex? 1 mg Filmtabletten, Camizestrant, LEUPRORELIN ACETATE, GOSERELIN, Nolvadex? 20 mg Filmtabletten, ABEMACICLIB
AstraZeneca AB, AstraZeneca AB, Sweden
ER+/HER2- Early Breast Cancer
 
 
UC-BCG-2501, 2025-520979-13-00: NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early breast cancer treated with Ribociclib (LEE-011) in the adjuvant setting

Recruiting
2/3
3306
Europe
DOXORUBICIN, ANASTROZOLE, LETROZOLE, PACLITAXEL ALBUMIN-BOUND, EXEMESTANE, RIBOCICLIB, GOSERELIN, TRIPTORELIN, DOCETAXEL, CYCLOPHOSPHAMIDE, PACLITAXEL, LEUPRORELIN, EPIRUBICIN
Unicancer, Novartis
Patients with HR+ HER2- early breast cancer at intermediate risk of recurrence and eligible for adjuvant chemotherapy
 
 
UC-BCG-2409/BIG 2402, 2024-519655-28-00: Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer

Not yet recruiting
2/3
2270
Europe
PACLITAXEL, LETROZOLE, DOCETAXEL, LEUPRORELIN ACETATE, ANASTROZOLE, EXEMESTANE, TAMOXIFEN, GOSERELIN, DOXORUBICIN, TRIPTORELIN, CYCLOPHOSPHAMIDE, EPIRUBICIN
Unicancer, Horizon Europe - Grant Agreement N?101156800
Premenopausal patients with high-risk HR-positive/HER2-negative breast cancer (BC) defined by tumour size and axillary lymph node status. One of the following must apply: a. 1-3 lymph nodes involved AND any invasive tumour size. b. node negative (including micrometastases in at least 1 node [i.e. deposit >0.2-2mm diameter]) AND invasive tumour size ? 50mm.
 
 
EORTC-2238-GUCG, 2023-506817-23-01: Improving impact of anti-androgen treatments on patient's daily life and their cancer

Recruiting
2/3
1209
Europe
ABIRATERONE , ENZALUTAMIDE , RELUGOLIX , TRIPTORELIN , DAROLUTAMIDE , LEUPRORELIN , DEGARELIX , APALUTAMIDE , GOSERELIN
European Organisation For Research And Treatment Of Cancer, EU grant (HORIZON 2022 RIA program)
Metastatic hormone na?ve prostate cancer (mHNPC)
 
 
CTR20132422: Evaluation of the safety and efficacy of immediate-release formulation of leuprolide acetate for injection

Suspended
2
China
1. Common Chinese name: Leuprorelin acetate injection; 1. Common Chinese name: Leuprorelin acetate microspheres for injection
Jilin Zixin Pharmaceutical Co., Ltd. / Jilin Aotai Pharmaceutical Technology Co., Ltd. / Shenyang Watson Pharmaceutical Research Institute
Indications: Prostate cancer
 
 
2014-000273-39: Trial investigating hormone injections, external beam radiotherapy and intravenous radionuclide injection in patients with advanced prostate cancer.

Ongoing
2
30
Europe
Solution for injection, Implant, , Powder and solvent for suspension for injection, Powder for suspension for injection, Xofigo 1000 kBq/mL solution for injection, Zoladex 3.6mg implant, Zoladex LA 10.8mg implant, Prostap SR DCS, Prostap 3 DCS, Decapeptyl SR 3mg, Decapeptyl SR 11.25mg
Belfast Health and Social Care Trust, Bayer PLC
Metastatic castration sensitive prostate cancer, Advanced prostate cancer, Diseases [C] - Cancer [C04]
 
 
ASN-002-IL, NCT02107391 / 2004-002708-13 / ACTRN12619001298101: Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer

Completed
2
63
RoW
Dendritic Cells DCVAC/PCa, Leuprolide acetate, Lupron, Goserelin Acetate, Zoladex
SOTIO a.s., Ascend Biopharmaceuticals Ltd
Basal Cell Carcinoma, Basal Cell Nevus Syndrome (BCNS)
12/15
06/16
2008-008722-73: ROLE OF PAROXETINE AS ADD-ON THERAPY TO GNRH AGONIST IN THE TREATMENT OF ENDOMETRIOSIS-RELATED CHRONIC PELVIC PAIN

Ongoing
2
40
Europe
ENANTONE*IM SC FL+SIR 11,25MG/, DAPAGUT*OS GTT 18,5ML20MG/20GO, ENANTONE*IM SC FL+SIR 11,25MG/, DAPAGUT*OS GTT 18,5ML20MG/20GO
AZIENDA OSPEDALIERA PISANA
Endometriosis-associated pelvic pain
 
 
2017-000154-19: A phase II randomized trial comparing alpelisib and fulvestrant versus chemotherapy as maintenance therapy in patients with PIK3CA mutated advanced breast cancer

Not yet recruiting
2
90
Europe
Alpelisib, BYL719, Tablet, Solution for injection, Implant in pre-filled syringe, Powder and solvent for solution for injection, FASLODEX, ZOLADEX, ENANTONE
UNICANCER, Novartis
PIK3CA mutated, HR+/Her2- metastatic breast cancer who do not present progressive disease after 6-8 cycles of 1st or second line chemotherapy., Breast cancer, Diseases [C] - Cancer [C04]
 
 
NCT00003915: Chemotherapy and Hormone Therapy in Treating Patients With Prostate Cancer

Active, not recruiting
2
63
US
bicalutamide, docetaxel, estramustine phosphate sodium, leuprolide acetate
University of Massachusetts, Worcester
Prostate Cancer
02/18
02/18
NCT02278185: Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

Completed
2
19
US
Enzalutamide, MDV3100, selective androgen receptor modulator MDV3100, XTANDI, leuprolide acetate, Enantone, LEUP, Lupron, Lupron Depot, goserelin acetate, ICI-118630, ZDX, Zoladex, histrelin acetate, Supprelin, Vantas, triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, D-TRP-6-LHRH, Decapeptyl, TRIP, degarelix, ASP3550, FE200486, Firmagon
University of Colorado, Denver
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
04/19
07/24
PH002-TP-II, NCT03272477 / 2016-005157-21: Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients

Completed
2
257
Europe
Perjeta Injectable Product, Pertuzumab, Herceptin, Trastuzumab, Tamoxifen, Paclitaxel, Epirubicin, Cyclophosphamide, Anastrozole, Letrozole, Exemestane, Leuprorelin acetate, Goserelin, Leuporelin acetate, Biopsy, Surgery
Palleos Healthcare GmbH, Roche Pharma AG, WSG WOMEN´S HEALTHCARE STUDY GROUP, Cankado GmbH
Breast Neoplasms
07/20
03/24
2020-004195-17: Stereotactic hypofractionated radiotherapy with or without hormonal therapy in prostate cancer patients Radioterapia stereotassica frazionata con o senza terapia ormonale nei pazienti con tumore alla prostata

Not yet recruiting
2
146
Europe
Enantone 3,75 mg/2ml polvere, Decapeptyl, Casodex, [027066125], [026999058], [031113020], Powder and solvent for dispersion for injection, Tablet
ISTITUTI FISIOTERAPICI OSPITALIERI
Unfavorable intermediate/high risk prostae cancer patients Pazienti affetti da neoplasia prostatica a rischio intermedio sfavorevole/alto rischio, Unfavorable intermediate/high risk prostae cancer patients Pazienti affetti da neoplasia prostatica a rischio intermedio sfavorevole/alto rischio, Diseases [C] - Cancer [C04]
 
 
NCT02058706: LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer

Completed
2
71
US
enzalutamide, MDV3100, selective androgen receptor modulator MDV3100, XTANDI, bicalutamide, Casodex, CDX, orchiectomy, leuprolide acetate, Enantone, LEUP, Lupron, Lupron Depot, goserelin acetate, ICI-118630, ZDX, Zoladex, laboratory biomarker analysis
Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
03/21
03/21
NCT02742675: Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)

Active, not recruiting
2
200
RoW
Bicalutamide, Casodex, goserelin acetate, Zoladex, flutamide, Eulexin, leuprolide acetate, Enantone, triptorelin, Diphereline, Definitive Treatment
Fudan University
Prostate Cancer
03/21
03/23
BYLieve, NCT03056755 / 2023-509167-24-00 / 2016-004586-67: Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

Checkmark Presentation of data from BYLieve trial for HR+/HER2- breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from BYLieve trial for HR+/HER2- breast cancer at SABCS 2022
Checkmark Data from BYLieve study for advanced breast cancer at ASCO 2020
May 2020 - May 2020: Data from BYLieve study for advanced breast cancer at ASCO 2020
Completed
2
383
Europe, Canada, Japan, US, RoW
Alpelisib, BYL719, Fulvestrant, Letrozole, Goserelin, Leuprolide
Novartis Pharmaceuticals, Novartis Pharma AG
Adult patients with PIK3CA mutant, HR-positive, HER2-negative advanced breast cancer
06/21
11/24
SAVE, NCT03899077 / 2018-004365-13: Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP

Recruiting
2
202
Europe
Apalutamide, Leuprorelin Acetate 45Mg Powder for Injection Suspension Vial, Goserelin Acetate 10.8 MG Subcutaneous Implant, Triptorelin Pamoate, Degarelix acetate
Cancer Research Antwerp, Janssen Pharmaceutica
Cancer of Prostate
08/25
12/25
NCT03043807: A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy

Completed
2
26
US
Leuprolide Acetate, Lupron Deport, Docetaxel, Texotere, Bicalutamide, Casodex, Radiation, Abiraterone Acetate, Zytiga
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
10/22
10/22
STARTAR, NCT03311555: A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy

Completed
2
39
US
Apalutamide, ARN-509, JNJ-56021927, Androgen deprivation, Salvage radiation therapy, Docetaxel
Andrew J. Armstrong, MD
Prostate Cancer
12/22
12/22
CARABELA, NCT04293393 / 2024-514395-40-00 / 2019-002123-15: Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

Active, not recruiting
2
200
Europe
Doxorubicin, Caelyx, Cyclophosphamide, Genoxal, Taxane, Paclitaxel, Docetaxel, Letrozole, Femara, Abemaciclib, Verzenios, LHRH Analogue, Goserelin, Leuprolide
Spanish Breast Cancer Research Group, Eli Lilly and Company
Early Breast Cancer
06/23
02/33
NCT03541928: Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery

Recruiting
2
60
US
HSV-Tk, Gene therapy, AdV-tk gene therapy, Herpes simplex virus thymidine kinase, Valacyclovir, Valtrex, Bicalutamide, Casodex, Leuprolide Acetate, Lupron, Brachytherapy, External beam radiotherapy, HDR, EBRT, Radical prostatectomy, Prostatectomy
The Methodist Hospital Research Institute
High-risk Prostate Cancer, Prostate Cancer
07/23
07/23
NCT06145308: Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Recruiting
2
39
RoW
Cohort 1 (HER2-positive, RC48-ADC), HER2,Vedolizumab, Cohort 2 (NTRK-fusion or NTRK-mutant), NTRK-inhibitor, Cohort 3 (AR-positive, leuprolide + bicalutamide + abiraterone), AR,leuprolide + bicalutamide + abiraterone, TROP2 ADC, Cohort 4 (TROP2 ADC), TKI, Cohort 5 (ACC-TKI), Albumin-paclitaxel + platinum, Cohort 6 (albumin-bound paclitaxel + platinum), Albumin-paclitaxel + carboplatin + apatinib + camrelizumab, Cohort 7 (albumin-bound paclitaxel + carboplatin + apatinib + camrelizumab), albumin-bound paclitaxel+trastuzumab+pyrotinib, Cohort8 (HER2-positive, albumin-bound paclitaxel + trastuzumab + pyrotinib), HER2,trastuzumab deruxtecan± pertuzumab, Cohort9(HER2-positive, DS-8201 ± pertuzumab), AR,AR antagonist ++ goserelin + pertuzumab + trastuzumab, Cohort 10 (HER2+/AR+, AR antagonist + goserelin + pertuzumab + trastuzumab), AR,AR antagonist +goserelin +docetaxel, Cohort 11 (AR-positive, AR antagonist + goserelin ± docetaxel), ivonescimab + investigator-choice platinum doublet+, Cohort 12 (ivonescimab), iparomlimab + tuvonralimab, Cohort 13 (iparomlimab + tuvonralimab), cadonilimab, Cohort 14 (cadonilimab), CDK4/6 inhibitor+AI or fulvestrant, Cohort 15 (HR-positive), alpelisib+fulvestrant, Cohort 16 (PI3K-mutant), PARP inhibitor, Cohort 17 (homologous-recombination-deficient), enfortumab vedotin, Cohort 18 (Nectin-4 ADC), HER2, pyrotinib + pertuzumab/trastuzumab, Cohort 19 (HER2-positive, pyrotinib + pertuzumab + trastuzumab), vebecotutamab ±lenvatinib, Cohort 20 (vebecotutamab ±lenvatinib)
Peking Union Medical College, Peking University Hospital of Stomatology
Salivary Gland Carcinoma, Precision Therapy
07/28
07/28
PLATO, NCT03900637: PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate

Active, not recruiting
2
122
RoW
Leuprorelin acetate, Leuplin, Letrozole, Lenara, Bretra, MammaPrint
Seoul National University Hospital
Breast Cancer
10/23
12/28
NeoChAI, NCT03497702: Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer

Recruiting
2
114
RoW
Doxorubicin, Cyclophosphamide, Docetaxel, Letrozole, leuprorelin
National Cancer Center, Korea
Breast Cancer, Invasive Breast Cancer
11/23
01/24
NCT01746849: Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

Active, not recruiting
2
82
US
Palifermin, Lupron, peripheral blood stem cell transplantation, Total-Body Irradiation (TBI), Thiotepa, Cyclophosphamide, Degarelix
Memorial Sloan Kettering Cancer Center, Swedish Orphan Biovitrum
Leukemia, Multiple Myeloma, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
12/26
12/26
 

Download Options